242 related articles for article (PubMed ID: 23572427)
1. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
2. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of inflammatory myopathies: a review.
Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rituximab in refractory antisynthetase syndrome.
Limaye V; Hissaria P; Liew CL; Koszyka B
Intern Med J; 2012 Mar; 42(3):e4-7. PubMed ID: 22432998
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Muscle Involvement in Antisynthetase Syndrome.
Noguchi E; Uruha A; Suzuki S; Hamanaka K; Ohnuki Y; Tsugawa J; Watanabe Y; Nakahara J; Shiina T; Suzuki N; Nishino I
JAMA Neurol; 2017 Aug; 74(8):992-999. PubMed ID: 28586844
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
11. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.
Rios Fernández R; Callejas Rubio JL; Sánchez Cano D; Sáez Moreno JA; Ortego Centeno N
Clin Exp Rheumatol; 2009; 27(6):1009-16. PubMed ID: 20149324
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
[TBL] [Abstract][Full Text] [Related]
15. [Antisynthetase myopathy].
Suzuki S
Rinsho Shinkeigaku; 2020 Mar; 60(3):175-180. PubMed ID: 32101845
[TBL] [Abstract][Full Text] [Related]
16. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
[TBL] [Abstract][Full Text] [Related]
19. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Troyanov Y; Targoff IN; Tremblay JL; Goulet JR; Raymond Y; Senécal JL
Medicine (Baltimore); 2005 Jul; 84(4):231-249. PubMed ID: 16010208
[TBL] [Abstract][Full Text] [Related]
20. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
Basnayake C; Cash K; Blumbergs P; Limaye V
Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]